ALK and lung carcinoma: In this study of 33 patients who received continued crizotinib therapy after RECIST-defined disease progression, the ORR and initial PFS time (PFS1) were consistent with those reported in phase 1-3 clinical trials of crizotinb monotherapy in patients with ALK-positive lung cancer [7, 8, 11].